Buy & Sell Oracle Corporation (ORCL) – Oracle Corporation Price Today
Aura AI Summary
Key Stats
- $554.04BMarket Cap
- TechnologySector
- -25.79%3M Drawdown
- $678.34BEnterprise Value
- 1.04%Dividend Yield
- 54% Buy | 46% SellTrading Activity
- 69 daysTypical Hold Time
Oracle Corporation (ORCL) is currently valued at a market capitalization of $554.04B, with an enterprise value of $678.34B. Over the past 52 weeks, Oracle Corporation has traded between a low of $136.39 and a high of $328.33, highlighting its annual price range. Over the past three months, Oracle Corporation has recorded a drawdown of -25.79%, reflecting recent price volatility. Oracle Corporation offers a dividend yield of 1.04%, with the most recent dividend of $0.50 paid on 09 Apr 26. On average, investors hold Oracle Corporation for approximately 69 days, indicating typical investor behavior on the platform.
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Most Recent News
Defiance ETFs launches SPCQ, a 2x inverse leveraged ETF targeting daily SpaceX stock declines.
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...

Halper Sadeh LLC probes fairness of recent major company sales and mergers for shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether shareholders of Open Lending Corporation, Nuvalent, Organon & Co., and SUNation Energy are receiving fair deals in their companies' recent sales or mergers. The firm suggests ins...

Global GLP-1 receptor agonist market to reach $95.3B by 2035, growing at 12.1% CAGR driven by diabetes and obesity demand.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
